Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer
Colorectal cancer (CRC) is one of the most lethal cancers worldwide, accounting for nearly ~10% of all cancer diagnoses and deaths. Current therapeutic approaches have considerably increased survival for patients diagnosed at early stages; however, ~20% of CRC patients are diagnosed with late-stage,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/6/1735 |
| _version_ | 1797612988411150336 |
|---|---|
| author | Rubi Campos Gudiño Kirk J. McManus Sabine Hombach-Klonisch |
| author_facet | Rubi Campos Gudiño Kirk J. McManus Sabine Hombach-Klonisch |
| author_sort | Rubi Campos Gudiño |
| collection | DOAJ |
| description | Colorectal cancer (CRC) is one of the most lethal cancers worldwide, accounting for nearly ~10% of all cancer diagnoses and deaths. Current therapeutic approaches have considerably increased survival for patients diagnosed at early stages; however, ~20% of CRC patients are diagnosed with late-stage, metastatic CRC, where 5-year survival rates drop to 6–13% and treatment options are limited. Genome instability is an enabling hallmark of cancer that confers increased acquisition of genetic alterations, mutations, copy number variations and chromosomal rearrangements. In that regard, research has shown a clear association between genome instability and CRC, as the accumulation of aberrations in cancer-related genes provides subpopulations of cells with several advantages, such as increased proliferation rates, metastatic potential and therapeutic resistance. Although numerous genes have been associated with CRC, few have been validated as predictive biomarkers of metastasis or therapeutic resistance. A growing body of evidence suggests a member of the High-Mobility Group A (<i>HMGA</i>) gene family, <i>HMGA2</i>, is a potential biomarker of metastatic spread and therapeutic resistance. <i>HMGA2</i> is expressed in embryonic tissues and is frequently upregulated in aggressively growing cancers, including CRC. As an architectural, non-histone chromatin binding factor, it initiates chromatin decompaction to facilitate transcriptional regulation. HMGA2 maintains the capacity for stem cell renewal in embryonic and cancer tissues and is a known promoter of epithelial-to-mesenchymal transition in tumor cells. This review will focus on the known molecular mechanisms by which HMGA2 exerts genome protective functions that contribute to cancer cell survival and chemoresistance in CRC. |
| first_indexed | 2024-03-11T06:48:37Z |
| format | Article |
| id | doaj.art-62e7e69a427147deb034cd3eba7d5a1f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T06:48:37Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-62e7e69a427147deb034cd3eba7d5a1f2023-11-17T10:06:29ZengMDPI AGCancers2072-66942023-03-01156173510.3390/cancers15061735Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal CancerRubi Campos Gudiño0Kirk J. McManus1Sabine Hombach-Klonisch2Department of Biochemistry & Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, CanadaDepartment of Biochemistry & Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, CanadaDepartment of Human Anatomy and Cell Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, CanadaColorectal cancer (CRC) is one of the most lethal cancers worldwide, accounting for nearly ~10% of all cancer diagnoses and deaths. Current therapeutic approaches have considerably increased survival for patients diagnosed at early stages; however, ~20% of CRC patients are diagnosed with late-stage, metastatic CRC, where 5-year survival rates drop to 6–13% and treatment options are limited. Genome instability is an enabling hallmark of cancer that confers increased acquisition of genetic alterations, mutations, copy number variations and chromosomal rearrangements. In that regard, research has shown a clear association between genome instability and CRC, as the accumulation of aberrations in cancer-related genes provides subpopulations of cells with several advantages, such as increased proliferation rates, metastatic potential and therapeutic resistance. Although numerous genes have been associated with CRC, few have been validated as predictive biomarkers of metastasis or therapeutic resistance. A growing body of evidence suggests a member of the High-Mobility Group A (<i>HMGA</i>) gene family, <i>HMGA2</i>, is a potential biomarker of metastatic spread and therapeutic resistance. <i>HMGA2</i> is expressed in embryonic tissues and is frequently upregulated in aggressively growing cancers, including CRC. As an architectural, non-histone chromatin binding factor, it initiates chromatin decompaction to facilitate transcriptional regulation. HMGA2 maintains the capacity for stem cell renewal in embryonic and cancer tissues and is a known promoter of epithelial-to-mesenchymal transition in tumor cells. This review will focus on the known molecular mechanisms by which HMGA2 exerts genome protective functions that contribute to cancer cell survival and chemoresistance in CRC.https://www.mdpi.com/2072-6694/15/6/1735HMGA2colorectal cancergenome instabilitymetastasistherapeutic resistance |
| spellingShingle | Rubi Campos Gudiño Kirk J. McManus Sabine Hombach-Klonisch Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer Cancers HMGA2 colorectal cancer genome instability metastasis therapeutic resistance |
| title | Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer |
| title_full | Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer |
| title_fullStr | Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer |
| title_full_unstemmed | Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer |
| title_short | Aberrant HMGA2 Expression Sustains Genome Instability That Promotes Metastasis and Therapeutic Resistance in Colorectal Cancer |
| title_sort | aberrant hmga2 expression sustains genome instability that promotes metastasis and therapeutic resistance in colorectal cancer |
| topic | HMGA2 colorectal cancer genome instability metastasis therapeutic resistance |
| url | https://www.mdpi.com/2072-6694/15/6/1735 |
| work_keys_str_mv | AT rubicamposgudino aberranthmga2expressionsustainsgenomeinstabilitythatpromotesmetastasisandtherapeuticresistanceincolorectalcancer AT kirkjmcmanus aberranthmga2expressionsustainsgenomeinstabilitythatpromotesmetastasisandtherapeuticresistanceincolorectalcancer AT sabinehombachklonisch aberranthmga2expressionsustainsgenomeinstabilitythatpromotesmetastasisandtherapeuticresistanceincolorectalcancer |